Capture and inception of bubbles near line vortices

Motivated by the need to predict vortex cavitation inception, a study has been conducted to investigate bubble capture by a concentrated line vortex of core size rcrc and circulation Γ0Γ0 under noncavitating and cavitating conditions. Direct numerical simulations that solve simultaneously for the two phase flow field, as well as a simpler one-way coupled point-particle-tracking model (PTM) were used to investigate the capture process. The capture times were compared to experimental observations. It was found that the point-particle-tracking model can successfully predict the capture of noncavitating small nuclei by a line vortex released far from the vortex axis. The nucleus grows very slowly during capture until the late stages of the process, where bubble/vortex interaction and bubble deformation become important. Consequently, PTM can be used to study the capture of cavitating nuclei by dividing the process into the noncavitating capture of the nucleus, and then the growth of the nucleus in the low-pressure core region. Bubble growth and deformation act to speed up the capture process.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/87832/2/022105_1.pd

Stromal podoplanin expression and its clinicopathological role in breast carcinoma

Introduction: Breast cancer is still a serious health problem in 21 st century and diagnosis, treatment and prognosis of this malignant disease are subject to many research. While cancer research has been focused on tumour cells primarily, recent studies showed that tumour stroma contribute to carcinogenesis as well as tumour cells. Especially fibroblasts adjacent to epithelial tumour cells are not ordinary fibroblasts and play the critical role. Studies showed that these cancer associated fibroblasts (CAFs) have different genetic profile and protein expression. One of the differently expressed molecules recently found is podoplanin. Podoplanin, utilised as a lymphatic endothelial marker, is found to be expressed in CAFs. The aim of this study is to evaluate the relationship between the stromal expression of podoplanin in invasive breast carcinoma and clinicopathological parameters. Materials & Methods: Podoplanin expression was evaluated immunohistochemically in 153 breast cancers. Tumours with ? 10% distinct cytoplasmic podoplanin staining in CAFs were considered as positive. Results: In 65.3% of analysed tumours, podoplanin expression was found positive in CAFs. According to our results, podoplanin positive CAFs correlated significantly with tumour size (p= 0.012), tumour grade (p= 0.032) and cerbB2 score (p= 0.032). Discussion: Our results suggest that podoplanin expression by CAFs could predict poor patient outcome in breast carcinoma. © 2018, Malaysian Society of Pathologists. All rights reserved

Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B

Tufan, Zeliha Kocak/0000-0002-3294-014X; Cosar, Arif Mansur/0000-0002-4472-2895; Cosar, Arif Mansur/0000-0002-4472-2895; Gulsen, Murat Taner/0000-0002-8531-9402;WOS: 000347835300007PubMed: 25982037BackgroundResults are conflicting with respect to the renal effects of anti-viral agents used for hepatitis B virus infection. AimTo compare short and long-term renal effects in real-life settings and to determine risk factors for renal impairment during treatment. Methods2221 treatment-naive patients were enrolled. Among these, 895 (302 lamivudine, 27 telbivudine, 282 entecavir, 273 tenofovir and 11 adefovir initiated patients) had repeated measures' of creatinine (baseline, 1st, 6th, 12th and 24th month of treatment). Telbivudine and adefovir groups were excluded from further analysis because of the low number of patients. We calculated the glomerular filtration rate (GFR) using the Modification of Diet in Renal Disease (MDRD) formula at each time point. Hypophosphataemia was also recorded. Risk factors for renal impairment were analysed. ResultsTenofovir caused a decline in GFR at each time point when compared to baseline levels. However, lamivudine and entecavir did not change GFR. GFR-shifting from 90 to 60-89mL/min/1.73m(2) was comparable among groups. The proportion of patients whose baseline creatinine increased more than 25% was comparable among all anti-virals. GFR showed a decline in patients who switched from entecavir to tenofovir. One patient with compensated cirrhosis needed to change from tenofovir because of renal safety. Seven and three patients developed transient hypophosphataemia in the tenofovir and lamivudine groups, respectively. ConclusionsAlthough tenofovir caused a decline in GFR, differences between the anti-viral agents do not appear to be so impressive. In patients with and without renal risk factors at baseline, there is no impact of anti-virals, including tenofovir